Waxman Renews Push For FDA Examination Of Phenylephrine Efficacy
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's decision to sell Claritin-D behind the counter rather than reformulate with the nasal decongestant phenylephrine has prompted Rep. Henry Waxman (D-Calif.) to renew his request for an FDA review of the ingredient's efficacy
You may also be interested in...
From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA
The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year
From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA
The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year
From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA
The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year